Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge.

08:00 EDT 12th September 2018 | BioPortfolio

Summary of "Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge."

Administration of influenza vaccines via the respiratory tract has potential benefits over conventional parenteral administration, inducing immunity directly at the site of influenza exposure as well as being needle free. In this study, we investigated the suitability of Advax™, a stable particulate polymorph of inulin, also referred to as delta inulin, as a mucosal adjuvant for whole inactivated influenza vaccine (WIV) administered either as a liquid or dry powder formulation. Spray freeze-drying produced Advax-adjuvanted WIV powder particles in a size range (1-5 μm) suitable for inhalation. The physical and biological characteristics of both WIV and Advax remained unaltered both by admixing WIV with Advax and by spray freeze drying. Upon intranasal or pulmonary immunization, both liquid and dry powder formulations containing Advax induced significantly higher systemic, mucosal and cellular immune responses than non-adjuvanted WIV formulations. Furthermore, pulmonary immunization with Advax-adjuvanted WIV led to robust memory B cell responses along with an increase of lung localization factors i.e. CXCR3, CD69, and CD103. A less pronounced but still positive effect of Advax was seen on memory T cell responses. In contrast to animals immunized with WIV alone, all animals pulmonary immunized with a single dose of Advax-adjuvanted WIV were fully protected with no visible clinical symptoms against a lethal dose of influenza virus. These data confirm that Advax is a potent mucosal adjuvant that boosts vaccine-induced humoral and cellular immune responses both in the lung and systemically with major positive effects on B-cell memory and complete protection against live virus. Hence, respiratory tract immunization, particularly via the lungs, with Advax-adjuvanted WIV formulation as a liquid or dry powder is a promising alternative to parenteral influenza vaccination.


Journal Details

This article was published in the following journal.

Name: Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995


DeepDyve research library

PubMed Articles [23553 Associated PubMed Articles listed on BioPortfolio]

Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge.

Bird to human transmission of high pathogenicity avian influenza virus (HPAIV) poses a significant risk of triggering a flu pandemic in the human population. Therefore, vaccination of susceptible poul...

Diminished B-cell response after repeat influenza vaccination.

Annual vaccination with influenza vaccines is recommended for protection against influenza in the United States. Past clinical studies and meta-analysis, however, have reported conflicting results on ...

Does influenza vaccination status change physician ordering patterns for respiratory viral panels? Inspection for selection bias.

Hospitalized patients with an acute respiratory illness (ARI) were compared to determine if demographic characteristics, timing or influenza vaccination biased who received clinical respiratory viral ...

Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains after Vaccination with Inactivated Trivalent Influenza Vaccine Vary with Age and Prior Year Vaccination.

Prior influenza immunity influences homologous neutralizing antibody responses elicited by inactivated influenza vaccines (IIV), but neutralizing antibody responses to heterologous strains have not be...

Changes in Influenza Vaccination Requirements for Health Care Personnel in US Hospitals.

Annual influenza vaccinations are currently recommended for all health care personnel (HCP) to limit the spread of influenza to those at high risk of developing serious complications from the virus. V...

Clinical Trials [12407 Associated Clinical Trials listed on BioPortfolio]

Safety and Immunogenicity of a Plasmid HIV Vaccine, ADVAX e/g + ADVAX p/n-t (ADVAX), in HIV Uninfected Adults.

The purpose of this study is to determine the safety and immune response to a investigational DNA Plasmid HIV vaccine, ADVAX e/g + ADVAX p/n-t (ADVAX), at three different dosage levels, in...

Study of Immune Responses to Influenza Vaccination

Better understanding of the immune responses to influenza vaccination is needed in order to understand situations of poor vaccine response. Adults will receive influenza vaccination and th...

A Trial to Evaluate the Safety and Immunogenicity of TBC-M4, an Env, Gag, Tat-Rev, and Nef-RT MVA HIV Vaccine and a Prime-Boost Regimen With ADVAX, an Env, Gag, Nef-Tat and Pol DNA HIV Vaccine and TBC-M4

This trial will study a prime-boost vaccine approach designed mainly to induce cell-mediated immune (CTL) responses. Two vaccine candidates will be used in two different prime-boost regime...

Genetic and Environmental Factors in the Response to Influenza Vaccination

The purpose of the study is to investigate and compare the cell responses to influenza vaccination in monozygotic (identical) and dizygotic (fraternal) twins to determine the roles of gene...

Kinetics of B-Cell Responses to Live Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age

This pilot study will investigate the peak of the post-immunization B-cell responses following vaccination with live, attenuated influenza vaccine in healthy children 2 years of age from b...

Medical and Biotech [MESH] Definitions

Group activities directed against VACCINATION.

Rate of VACCINATION as defined by GEOGRAPHY and or DEMOGRAPHY.

Species of the genus INFLUENZAVIRUS B that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed.

Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.

Refusal to receive VACCINATION.

Quick Search


DeepDyve research library

Relevant Topics

Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Searches Linking to this Article